|BRILINTA 90 mg + ASPIRIN (N=9235)||CLOPIDOGREL + ASPIRIN (N=9186)|
|OVERALL RATE OF DYSPNEA||14%||8%|
|DISCONTINUATION DUE TO DYSPNEA||0.9%||0.1%|
Patients may be counted in more than 1 event category. Patients with multiple events in the same category being tabulated are counted only once within that category.2
Dyspnea was prospectively evaluated in the PLATO trial. At enrollment, PLATO investigators were asked to record whether there was a history of dyspnea and/or current dyspnea and record occurrences of dyspnea as adverse events (AEs) or serious adverse events (SAEs) throughout the trial.3
|BRILINTA 60 mg + ASPIRIN (N=6958)||ASPIRIN alone (N=6996)|
|OVERALL RATE OF DYSPNEA||14%||6%|
|DISCONTINUATION DUE TO DYSPNEA||4.3%||0.7%|
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.